Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by a lack of estrogen receptor (ER), progesterone receptor (PR), and HER2, and comprise approximately 15–20% of breast cancers [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.